Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina

Chagas' Disease Clinical Trial

Official title:
Effectiveness of Nifurtimox in Patients With Chagas' Disease Based on Data From Patient Medical Records in Argentina: a Retrospective Medical Chart Review Study

Status Completed

Clinical Trial Summary

The researchers in this trial want to analyze prerecorded patient data which provide information on benefits of the drug nifurtimox in patients with a sudden (acute) and long lasting (chronic) Chagas´ disease an illness caused by parasites mostly transmitted to humans by a bug. They also want to learn how often organs, especially the heart, are affected by the illness in treated and untreated chronic Chaga's patients. In order to find this out medical records of adult and pediatric patients in Argentina will be analyzed.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03784391
Study type	Observational
Source	Bayer
Contact
Status	Completed
Phase
Start date	December 14, 2018
Completion date	April 6, 2020

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT01549236` - Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease	Phase 4
	Completed	`NCT03334838` - Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study	Phase 1